Anti-claudin 18.2 antibodies
US11485782B2 · kind B2 · utility
0Cited by
58References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2019 |
| Grant date | Nov 1, 2022 |
| Priority date | — |
| Expiry date | Jul 15, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/705
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are anti-claudin 18.2 (CLDN18.2) antibodies and fragments thereof. Also provided are isolated nucleic acid molecules that encode anti-CLDN18.2 antibodies, vectors comprising such nucleic acid, and host cells comprising such vectors or nucleic acids. Provided are methods of making anti-CLDN18.2. Also provided are related pharmaceutical compositions and methods using such pharmaceutical compositions in the treatment of disorders associated with aberrant CLDN18.2 expression, such as cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.